Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point
Meletios Α. Dimopoulos(Korea University), A. Palumbo(University of Turin), J. Catalano(Frankston Hospital), MT Petrucci(Sapienza University of Rome), Evangelos Terpos(National and Kapodistrian University of Athens), Ludger Grote(Sahlgrenska University Hospital), Jianqi Zhang(Chinese Academy of Sciences), Martin Kropff(University Hospital Münster), Christian Jacques(Bibliothèque et Archives nationales du Québec), Robin Foà(Sapienza University of Rome)
Cited by 30
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Ultrathin metal–organic framework nanosheets for electrocatalytic oxygen evolution
|Nature Energy|2016|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k